On Aug. 23, the U.S. Food and Drug Administration granted full approval to the Pfizer-BioNTech coronavirus vaccine, which is a significant milestone in the pandemic. It is the first licensing of a vaccine for the novel coronavirus.
The COVID-19 vaccine now is approved by the U.S. Food and Drug Administration (FDA).
The FDA said in its press release that the vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals, the agency said.
“The FDA’s approval of this vaccine is a milestone as we continue to battle the COVID-19 pandemic. While this and other vaccines have met the FDA’s rigorous, scientific standards for emergency use authorization, as the first FDA-approved COVID-19 vaccine, the public can be very confident that this vaccine meets the high standards for safety, effectiveness, and manufacturing quality the FDA requires of an approved product,” said Acting FDA Commissioner Janet Woodcock, MD. “While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated. Today’s milestone puts us one step closer to altering the course of this pandemic in the U.S.”
The Pfizer-BioNTech COVID-19 Vaccine has been available under emergency use authorization (EUA) in individuals 16 years of age and older since Dec. 11, 2020, the FDA said, and the authorization was expanded to include those 12 through 15 years of age on May 10, 2021.
Reference
The FDA approves first COVID-19 vaccine. The U.S. Food and Drug Administration. Accessed August 23, 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine
Contemporary OB/GYN Senior Editor Angie DeRosa gets insight on the current state of COVID-19 from Christina Han, MD, division director of maternal-fetal medicine at the University of California, Los Angeles, and member of its COVID-19 task force. Han is an active member of the Society for Maternal-Fetal Medicine and discusses the issues on behalf of SMFM.
Listen
NAID report shows maternal COVID-19 vaccination protects newborns
April 4th 2024New research led by the National Institute of Allergy and Infectious Diseases reveals sustained antibody levels in infants born to vaccinated mothers, underscoring the importance of maternal vaccination in safeguarding newborns against COVID-19.
Read More
Decreased adolescent pregnancy and sexual health care during COVID-19 pandemic
February 13th 2024Adolescent pregnancy and sexual health care utilization declined during the COVID-19 pandemic, indicating significant disruptions in reproductive health services for young females, as highlighted in a recent study published in Pediatrics.
Read More
COVID-19 vaccination during pregnancy not linked to preterm birth
January 31st 2024A systematic review of 6 studies revealed that COVID-19 vaccination during pregnancy does not significantly increase the risk of preterm birth, providing crucial insights for public health policies and offering reassurance to healthcare providers and expectant mothers.
Read More